Results 21 to 30 of about 2,224,846 (160)

KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)

Scientific Reports, 2021
Non-small cell lung cancer (NSCLC) has a poor prognosis with a 5 year survival rate of only ~ 10%. Important driver mutations underlying NSCLC affect the epidermal growth factor receptor (EGFR) causing the constitutive activation of its tyrosine kinase ...
Felix Glaser, Petra Hundehege, Etmar Bulk, Luca Matteo Todesca, Sandra Schimmelpfennig, Elke Nass, Thomas Budde, Sven G. Meuth, Albrecht Schwab   +8 more
doaj   +1 more source

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer

Cells, 2022
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2)
Chike Osude, Leo Lin, Meet Patel, Adam Eckburg, Joseph Berei, Adijan Kuckovic, Namrata Dube, Aayush Rastogi, Shruti Gautam, Thomas J. Smith, Shylendra B. Sreenivassappa, Neelu Puri   +11 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh, Martin Clynes, Rizwan Sheikh, Sheikh, Rizwan, O'Connor, Robert A., Robert O’Connor, Ray McDermott, O'Connor, Robert, Clynes, Martin, Walsh, Naomi, McDermott, Ray   +10 more
core   +1 more source

Identification of novel epigenetic mediators of erlotinib resistance in non-small cell lung cancer

, 2020
Lung cancer is the third most prevalent cancer in the world; however it is the leading cause of cancer related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of the lung cancer cases. The current strategies to treat NSCLC patients
Arpita S Pal (8612079)
core   +3 more sources

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]

, 2008
Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Pawel, Joachim, Wagner, Horst, Poellinger, Barbara, Duell, Thomas   +3 more
core   +1 more source

Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer

Scientific Reports, 2022
The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal growth factor receptor inhibitors (EGFRi) and to identify drugs that are cytotoxic once EGFRi ...
Narmeen S. Rashid, David C. Boyd, Amy L. Olex, Jacqueline M. Grible, Alex K. Duong, Mohammad A. Alzubi, Julia E. Altman, Tess J. Leftwich, Aaron D. Valentine, Nicole S. Hairr, Emily K. Zboril, Timothy M. Smith, Adam D. Pfefferle, Mikhail G. Dozmorov, J. Chuck Harrell   +14 more
doaj   +1 more source

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib [PDF]

, 2022
Introduction: The hepatocyte growth factor receptor MET represents a resistance mechanism to epidermal growth factor receptor (EGFR) inhibition in EGFR mutant (mt) non–small cell lung cancer (NSCLC).
Juan-Vidal, Oscar, Wijayawardana, Sameera R., Grosch, H., Smit, Egbert, Moran, T., Smit, E., Camidge, D. Ross, Bepler, G., Goldman, J.W., Wacheck, V., Wijayawardana, S.R., Demedts, Ingel, Juan-Vidal, O., Camidge, D.R., Molina, J., Park, K., Park, Keunchil, Molina, Julian, Bepler, Gerold, Goldman, Jonathan W., Wacheck, Volker, Mileham, Kathryn, Wang, Xuejing Aimee, Wang, X.J.A., Wallin, J., Grosch, Heidrun, Mileham, K., Wallin, Johan, Moran, Teresa, Demedts, I.   +29 more
core   +1 more source

Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer

Di-san junyi daxue xuebao, 2020
Objective To observe the expression of hexokinase 2 (HK2), a key enzyme of glycolysis, in human non-small cell lung cancer (NSCLC) tissues, and to investigate the role and mechanism of HK2 in the resistance of NSCLC to erlotinib. Methods The relationship
YOU Qi, ZHUO Wenlei, CHEN Zhengtang
doaj   +1 more source

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer

Pharmacological Research, 2023
Nearly half of all Asian non-small cell lung cancer (NSCLC) patients harbour epidermal growth factor receptor (EGFR) mutations, and first-generation EGFR tyrosine kinase inhibitors (TKIs) are one of the first-line treatments that have improved the ...
Cong Xu, Ze-Bo Jiang, Le Shao, Zi-Ming Zhao, Xing-Xing Fan, Xinbing Sui, Li-Li Yu, Xuan-Run Wang, Ruo-Nan Zhang, Wen-Jun Wang, Ya-Jia Xie, Yi-Zhong Zhang, Xiao-Wen Nie, Chun Xie, Ju-Min Huang, Jing Wang, Jue Wang, Elaine Lai-Han Leung, Qi-Biao Wu   +18 more
doaj   +1 more source

Novel therapeutic targets in NSCLC resistance to Erlotinib [PDF]

, 2017
Approximately 10% of non-small cell lung cancers (NSCLCs) have an activating mutation within the kinase domain of epidermal growth factor receptor (EGFR). Competitive tyrosine kinase inhibitors (TKIs), such as Erlotinib and Gefitinib, have been developed
Chater, Emily
core   +1 more source